Hanmi Pharm announces a Chinese sales license agreement of new lung cancer treatment with ZAI Lab

Published: 2015-11-25 09:27:04

Updated: 2015-11-25 11:25:35

On the 23^rd, Hanmi Pharm(CEO Kwan-soon Lee) announced an exclusive license agreement to handle the self-developed targeted lung cancer treatment(HM61713) across China(including Hong Kong and Macao) with ZAI Lab, a Chinese life science company.

With the agreement, ZAI Lab acquired an exclusive license to jointly develop and commercialize HM61713 across China. Hanmi Pharm established a global li...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.

Hanmi Pharm announces a Chinese sales license agreement of new lung cancer treatment with ZAI Lab

On the 23rd, Hanmi Pharm(CEO Kwan-soon Lee) announced an exclusive license agreement to handle the self-developed targeted lung cancer treatment(HM61713) across China(including Hong Kong and Macao) with ZAI Lab, a Chinese life science company.

Fees

On the 23^rd, Hanmi Pharm(CEO Kwan-soon Lee) announced an exclusive license agreement to handle the self-developed targeted lung cancer treatment(HM61713) across China(including Hong Kong and Macao) with ZAI Lab, a Chinese life science company.